Skip to Main Content (Press Enter)

Logo UNICH
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNICH

|

UNI-FIND

unich.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Bioengineered Human Stromal Lenticule for Recombinant Human Nerve Growth Factor Release: A Potential Biocompatible Ocular Drug Delivery System

Articolo
Data di Pubblicazione:
2022
Abstract:
Small incision lenticule extraction (SMILE), is a surgical procedure for the myopia correction, during which a corneal stromal lenticule is extracted. Given that we have previously demonstrated how this discarded tissue could be repurposed as a bio-scaffold for stromal engineering, this study aimed to explore its use as an ocular drug delivery system of active molecules, using neurotrophic factor Nerve Growth Factor (NGF). We employed human stromal lenticules directly collected from healthy donors undergoing SMILE. Following a sodium dodecylsulfate (SDS) treatment, decellularized lenticules were incubated with a suspension of polylactic-co-glycolic-acid (PLGA) microparticles (MPs) loaded with recombinant human NGF (rhNGF-MPs). Fluorescent MPs (Fluo-MPs) were used as control. Data demonstrated the feasibility to engineer decellularized lenticules with PLGA-MPs which remain incorporated both on the lenticules surface and in its stromal. Following their production, the in vitro release kinetic showed a sustained release for up to 1 month of rhNGF from MPs loaded to the lenticule. Interestingly, rhNGF was rapidly released in the first 24 h, but it was sustained up to the end of the experiment (1 month), with preservation of rhNGF activity (around 80%). Our results indicated that decellularized human stromal lenticules could represent a biocompatible, non-immunogenic natural scaffold potential useful for ocular drug delivery. Therefore, combining the advantages of tissue engineering and pharmaceutical approaches, this in vitro proof-of-concept study suggests the feasibility to use this scaffold to allow target release of rhNGF in vivo or other pharmaceutically active molecules that have potential to treat ocular diseases.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
decellularization; drug delivery; microparticles; nerve growth factor; scaffold; smile; stromal lenticule; tissue engineering
Elenco autori:
Mastropasqua, Leonardo; Nubile, Mario; Acerra, Giuseppina; Detta, Nicola; Pelusi, Letizia; Lanzini, Manuela; Mattioli, Simone; Santalucia, Manuela; Pietrangelo, Laura; Allegretti, Marcello; Dua, Harminder S; Mehta, Jodhbir S; Pandolfi, Assunta; Mandatori, Domitilla
Autori di Ateneo:
MANDATORI DOMITILLA
MASTROPASQUA Leonardo
NUBILE MARIO
PANDOLFI Assunta
PIETRANGELO LAURA
Pelusi Letizia
Link alla scheda completa:
https://ricerca.unich.it/handle/11564/786470
Link al Full Text:
https://ricerca.unich.it//retrieve/handle/11564/786470/332762/Mastropasqua%20and%20Nubiele,%202022.pdf
Pubblicato in:
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
Journal
  • Dati Generali

Dati Generali

URL

https://www.frontiersin.org/articles/10.3389/fbioe.2022.887414/full
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 25.5.0.1